Altimmune, Inc. (ALT): Price and Financial Metrics
ALT Price/Volume Stats
| Current price | $5.62 | 52-week high | $11.16 |
| Prev. close | $5.46 | 52-week low | $3.55 |
| Day low | $5.47 | Volume | 3,875,200 |
| Day high | $5.81 | Avg. volume | 2,451,334 |
| 50-day MA | $5.15 | Dividend yield | N/A |
| 200-day MA | $6.56 | Market Cap | 455.82M |
ALT Stock Price Chart Interactive Chart >
Altimmune, Inc. (ALT) Company Bio
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
ALT Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALT Price Returns
| 1-mo | -3.10% |
| 3-mo | 0.90% |
| 6-mo | -41.70% |
| 1-year | -12.94% |
| 3-year | -11.77% |
| 5-year | -19.14% |
| YTD | -22.05% |
| 2024 | -35.91% |
| 2023 | -31.61% |
| 2022 | 79.59% |
| 2021 | -18.79% |
| 2020 | 496.83% |